# Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

> **NCT05135442** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura, Acquired

## Interventions

- **DRUG:** Bortezomib Injection

## Key facts

- **NCT ID:** NCT05135442
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05135442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05135442, "Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05135442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*